Last reviewed · How we verify
Intensive treatment
Intensive treatment is a Small molecule drug developed by Innovent Biologics (Suzhou) Co. Ltd.. It is currently FDA-approved. Also known as: Poor response to previous biologic therapy.
Inhibits programmed death-ligand 1 (PD-L1) to restore T-cell mediated immune response against cancer cells.
Intensive treatment involves interventions such as regular insulin and exercise, which are studied in conditions including acute coronary syndrome and Parkinson disease. The modality of intensive treatment is a small molecule, although the specific compound is not specified in the provided information.
At a glance
| Generic name | Intensive treatment |
|---|---|
| Also known as | Poor response to previous biologic therapy |
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
By blocking PD-L1, the drug prevents cancer cells from evading immune detection, allowing the immune system to attack and destroy the cancer cells. This mechanism is based on the principle of immune checkpoint inhibition, which has been shown to be effective in treating various types of cancer.
Approved indications
Common side effects
Key clinical trials
- "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" (NA)
- BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- Virtual Reality (VR) NATURE - Alcohol Use Disorder (AUD) (NA)
- KD Treatment for Super-refractory Status Epilepticus (NA)
- Closed Loop Glucose Control in Patients With Type 2 Diabetes (NA)
- Effects of Intensive Virtual Reality-Based Balance and Gait Training on Activity Performance and Quality of Life in Subacute Stroke Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intensive treatment CI brief — competitive landscape report
- Intensive treatment updates RSS · CI watch RSS
- Innovent Biologics (Suzhou) Co. Ltd. portfolio CI
Frequently asked questions about Intensive treatment
What is Intensive treatment?
How does Intensive treatment work?
Who makes Intensive treatment?
Is Intensive treatment also known as anything else?
What development phase is Intensive treatment in?
Related
- Manufacturer: Innovent Biologics (Suzhou) Co. Ltd. — full pipeline
- Also known as: Poor response to previous biologic therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing